Protective Effects of Human Lactoferrin during Aggregatibacter actinomycetemcomitans-Induced Bacteremia in Lactoferrin-Deficient Mice

Velusamy, Senthil Kumar; Poojary, R.; Ardeshna, R.; Alabdulmohsen, Waad; Fine, Daniel H.; Velliyagounder, Kabilan

doi:10.1128/aac.00020-13

Cited by 27 publications

(24 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The recovered streptomycin resistant colonies were confirmed by PCR [5]. The hLF (100 μg/g body wt) for the prophylactic treatment was prepared as reported earlier [10]. …”

Section: Methodsmentioning

confidence: 99%

“…Mice (n=5–8) were euthanized at 6, 12, 48 and 96 h following injection of either S. mutans or hLF or both. The recovered S. mutans were expressed in CFU/ml or CFU/g tissue in three independent experiments and the data were statistically analyzed using one-way ANOVA as described earlier [10]. …”

Section: Methodsmentioning

confidence: 99%

“…The major ability of LF is to induce the innate immune mediator cells that subsequently impact the adaptive immune cell functions. Also, the affinity of LF towards iron is considered as a main component of non-specific host defense system against numerous pathogens [8–10]. High level of plasma LF concentration has been suggested to be a predictive indicator of sepsis-related morbidity and mortality [11].…”

Section: Introductionmentioning

confidence: 99%

“…We have recently demonstrated the importance of the host LF against the Gram-negative periodontal pathogen, Aggregatibacter actinomycetemcomitans [19]. Subsequently, we have also reported the effect of human lactoferrin (hLF) against A. actinomycetemcomitans -induced experimental bacteremia [10]. Prophylactic treatment of hLF against Gram-positive bacteria S. mutans -induced bacteremia however, has not been studied to date.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Prophylactic effect of human lactoferrin against Streptococcus mutans bacteremia in lactoferrin knockout mice

Velusamy

Fine

Velliyagounder

2014

Microbes and Infection

View full text Add to dashboard Cite

Streptococcus mutans is the primary agent of dental caries, which is often detected in transient bacteremia. Lactoferrin is a multifunctional glycoprotein showing antibacterial activities against several Streptococcus species. We reported here the prophylactic effect of human lactoferrin (hLF) in a lactoferrin knockout mouse (LFKO−/−) bacteremic model. The hLF treatment significantly cleared S. mutans from the blood and organs of bacteremic mice when compared to the non-hLF treated mice. Further, analysis of serum cytokines, spleen and liver cytokine mRNA levels revealed that hLF prophylaxis modulates their release differently when compared to the non-hLF treated group. C-reactive protein level (P=0.003) also decreased following hLF prophylaxis in S. mutans induced bacteremic mice. Additional quantitative RT-PCR analysis revealed that hLF prophylaxis significantly decreased the expression level of IFN-γ, TNF-α, IL-1β, IL-6, MPO and iNOS in spleen and liver. These results suggested that the hLF protects the host against S. mutans-induced experimental bacteremia.

show abstract

“…The recovered streptomycin resistant colonies were confirmed by PCR [5]. The hLF (100 μg/g body wt) for the prophylactic treatment was prepared as reported earlier [10]. …”

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Prophylactic effect of human lactoferrin against Streptococcus mutans bacteremia in lactoferrin knockout mice

Velusamy

Fine

Velliyagounder

2014

Microbes and Infection

View full text Add to dashboard Cite

show abstract

“…Our studies demonstrated that Lactoferrin knockout (LFKO -/-) mice are more susceptible to A. actinomycetemcomitans-induced periodontal disease and bacteremia [33,34], S. mutans-induced bacteremia [35], and C. albicans induced oral candidiasis [36] when compared to WT or LFKO -/-mice administered human LF.…”

Section: Introductionmentioning

confidence: 99%

Diabetic Lactoferrin Deficient Mice Demonstrates Greater Susceptibility to Experimental Periodontal Disease

et al. 2015

View full text Add to dashboard Cite

The objective of this study is to determine whether alloxaninduced diabetic Lactoferrin knockout (LFKO -/-) mice are more susceptible to periodontal disease caused by Aggregatibacter actinomycetemcomitans compared to the diabetic wild-type (WT) mice. Diabetes was induced in mice by a single dose of alloxan (60 mg/kg) injected intravenously. Mice were categorized as diabetic when blood glucose levels >250 mg/dL were measured on the 7 th day after the injection. Periodontal disease was experimentally induced by A. actinomycetemcomitans infection in alloxan induced diabetic WT and LFKO -/-mice. Fasting blood glucose levels and body weight were monitored throughout the study. At the end of the 12 th week of infection, mice were sacrificed and bone loss among the groups was estimated by measuring the distance between cemento-enamel junction (CEJ) to the alveolar bone crest (ABC) at 12 sites on the molars. A. actinomycetemcomitans infected mice groups developed more alveolar bone loss than sham-infected animals. Diabetic LFKO

show abstract

Antibacterial and Anti‐biofilm Activity of the Human Breast Milk Glycoprotein Lactoferrin against Group B Streptococcus

Francis

Guevara

et al. 2021

ChemBioChem

View full text Add to dashboard Cite

Group B Streptococcus (GBS) is an encapsulated Gram‐positive human pathogen that causes invasive infections in pregnant hosts and neonates, as well as immunocompromised individuals. Colonization of the human host requires the ability to adhere to mucosal surfaces and circumnavigate the nutritional challenges and antimicrobial defenses associated with the innate immune response. Biofilm formation is a critical process to facilitate GBS survival and establishment of a replicative niche in the vertebrate host. Previous work has shown that the host responds to GBS infection by producing the innate antimicrobial glycoprotein lactoferrin, which has been implicated in repressing bacterial growth and biofilm formation. Additionally, lactoferrin is highly abundant in human breast milk and could serve a protective role against invasive microbial pathogens. This study demonstrates that human breast milk lactoferrin has antimicrobial and anti‐biofilm activity against GBS and inhibits its adherence to human gestational membranes. Together, these results indicate that human milk lactoferrin could be used as a prebiotic chemotherapeutic strategy to limit the impact of bacterial adherence and biofilm formation on GBS‐associated disease outcomes.

show abstract

Protective Effects of Human Lactoferrin during Aggregatibacter actinomycetemcomitans-Induced Bacteremia in Lactoferrin-Deficient Mice

Cited by 27 publications

References 44 publications

Prophylactic effect of human lactoferrin against Streptococcus mutans bacteremia in lactoferrin knockout mice

Prophylactic effect of human lactoferrin against Streptococcus mutans bacteremia in lactoferrin knockout mice

Diabetic Lactoferrin Deficient Mice Demonstrates Greater Susceptibility to Experimental Periodontal Disease

Antibacterial and Anti‐biofilm Activity of the Human Breast Milk Glycoprotein Lactoferrin against Group B Streptococcus

Contact Info

Product

Resources

About